Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc. today announced data from a post-hoc analysis examining progression-free survival following treatment with ADCETRISA versus last prior therapy in patients diagnosed with relapsed or refractory Hodgkin lymphoma post-autologous stem cell transplant or relapsed or refractory systemic ... (more)
http://www.businesswire.com/news/topix/20130619005627/en
http://www.businesswire.com/news/topix/20130619005627/en
No comments:
Post a Comment